Drugs / HSK47388
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06926218 | May → Jul 2025 overdue | — | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07335055 | Feb 2026 → Oct 2027 expected | ulcerative colitis | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07158268 | Sep 2025 → Dec 2026 expected | psoriasis | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK47388 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06926218 ↗ |
| Route | Oral | “Single oral doses of HSK47388” NCT06926218 ↗ |